Similarly, patients with TP53-disrupted mantle cell lymphoma (MCL) or Burkitt lymphoma (BL) may not benefit from intensive chemotherapy, ASCT, or other targeted treatment strategies26–29. This evidence concerns the gene TP53 and Burkitt lymphoma.